Asciminib

Phase 1Recruiting

1 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Conditions

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Trial Timeline

Jan 1, 2026 → Nov 1, 2029

NCT ID

NCT07250087

About Asciminib

Asciminib is a phase 1 stage product being developed by Novartis for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07250087. Target conditions include Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.

What happened to similar drugs?

2 of 8 similar drugs in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia were approved

Approved (2) Terminated (1) Active (5)

✅NilotinibNovartisApproved

✅AsciminibNovartisApproved

❌NilotinibNovartisPhase 3

🔄NilotinibNovartisPhase 3

🔄Asciminib + NilotinibNovartisPhase 3

🔄Imatinib + Nilotinib + Bosutinib + Dasatinib + AsciminibNovartisPhase 3

🔄Blinatumomab + Blinatumomab + HyperCVADAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04360005	Pre-clinical	Active	—	—	Chronic Myeloid Leukemia in Chronic Phase
NCT07250087	Phase 1	Recruiting	Jan 1, 2026	Nov 1, 2029	Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT06629584	Phase 2	Recruiting	Feb 14, 2025	Dec 31, 2028	Malignant Solid Tumors
NCT06427811	Approved	Active	Nov 28, 2024	Nov 1, 2026	Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
NCT06236724	Phase 2	Recruiting	Jan 31, 2024	Jul 1, 2035	Chronic Myeloid Leukemia
NCT05384587	Phase 2	Active	Nov 11, 2022	Oct 17, 2027	Chronic Myelogenous Leukemia - Chronic Phase
NCT04795427	Phase 2	Completed	Dec 6, 2021	Nov 18, 2024	Leukemia, Chronic Myelogenous
NCT03605277	Phase 1	Completed	Nov 16, 2018	Apr 14, 2019	Renal Impairment

Competing Products

20 competing products in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

See all competitors

Product	Company	Stage	Hype Score
Imatinib Mesylate	Novartis	Phase 2	35
Nilotinib	Novartis	Phase 3	32
Nilotinib	Novartis	Phase 3	40
STI571 400 mg + STI571 600 mg	Novartis	Phase 2	35
Induction Phase + Re-Induction Phase + Post-Remission + Maintenance	Novartis	Phase 2	42
nilotinib	Novartis	Phase 2	35
Asciminib + Nilotinib	Novartis	Phase 3	44
imatinib mesylate	Novartis	Phase 2	35
Blinatumomab + Asciminib	Novartis	Phase 1/2	39
Asciminib Pediatric formulation group + Asciminib Adult formulation group	Novartis	Phase 1/2	39
Nilotinib + LDE225	Novartis	Phase 1	29
Nilotinib	Novartis	Approved	43
Imatinib + Nilotinib + Bosutinib + Dasatinib + Asciminib	Novartis	Phase 3	44
Asciminib	Novartis	Approved	47
Blinatumomab	Amgen	Phase 2	35
Treatment with blinatumomab given subcutaneously.	Amgen	Phase 2	42
Blinatumomab + Blinatumomab + HyperCVAD	Amgen	Phase 3	47
Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen	Amgen	Phase 3	47
Bosutinib	Pfizer	Phase 1/2	36
Bosutinib + Bosutinib	Pfizer	Phase 1	29